Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 4Gynecologic 3Lymphoid 2Sarcoma 1Other solid neoplasm 1Gastrointestinal 1Breast 1

Conditions

Recurrence 3Ovarian Neoplasms 3

Interventions

Paclitaxel 192Carboplatin 159pembrolizumab 118Bevacizumab 86liposomal doxorubicin 68Gemcitabine 62Cisplatin 55olaparib 49Topotecan 47Nivolumab 32niraparib 30Cyclophosphamide 30Doxorubicin 29Docetaxel 261-dodecylpyridoxal 22Injections 21Drug Therapy 20human papillomavirus vaccine, L1 type 16, 18 19fludarabine 18atezolizumab 18Pemetrexed 18lenvatinib 17mirvetuximab soravtansine 16Fulvestrant 16avelumab 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15durvalumab 14Oxaliplatin 13Irinotecan 13Fluorouracil 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × chiauranib × Gynecologic × Clear all
NCT04921527 2024-10-18

CHIPRO

Chipscreen Biosciences, Ltd.

Phase 3 Recruiting
454 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT03901118 2021-03-19

Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer

Chipscreen Biosciences, Ltd.

Phase 2 Completed
47 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT03166891 2020-01-18

Phase Ib Study of Chiauranib in Patients With Ovarian Cancer

Chipscreen Biosciences, Ltd.

Phase 1/2 Completed
25 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡